Welcome to our dedicated page for Vivos Therapeutics SEC filings (Ticker: VVOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vivos Therapeutics, Inc. (NASDAQ: VVOS) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a medical technology issuer focused on obstructive sleep apnea (OSA) and related sleep-disordered breathing conditions, Vivos uses its SEC reports to describe its business, device portfolio, acquisitions, financing activities and governance matters.
Through periodic reports such as Forms 10-K and 10-Q, investors can review detailed discussions of Vivos’ operations, including its Complete Airway Repositioning and/or Expansion (CARE) devices, DNA appliance, Vivos Guides, VidaSleep oral appliance and related clinical and commercial initiatives. These filings also explain the company’s strategy of acquiring or affiliating with sleep centers, such as The Sleep Center of Nevada, and its revised OSA provider management model that uses jointly owned management entities.
Current reports on Form 8-K and amendments (8-K/A) highlight specific material events, including the completion of acquisitions, integration updates for sleep centers, clinical data announcements, changes to at-the-market offering programs, and the scheduling or results of stockholder meetings. Proxy statements on Form DEF 14A provide additional detail on board composition, equity incentive plans and matters submitted to stockholders for approval.
On Stock Titan, these VVOS filings are complemented by AI-powered tools that help summarize lengthy documents and highlight key sections, such as risk factor updates, acquisition terms, and descriptions of new management or affiliation agreements. Users can also monitor items like late-filing notifications on Form 12b-25 and other compliance-related submissions. Together, the filings and AI analysis offer a structured view of how Vivos reports its evolving sleep apnea device business and sleep center operations to regulators and investors.
Vivos Therapeutics received a Nasdaq notice on April 17, 2026 that its stockholders’ equity reported in its 2025 annual report does not meet Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million of stockholders’ equity. As of December 31, 2025, the company reported negative stockholders’ equity of about $1.55 million.
Vivos has since completed two equity financings in the first quarter of 2026 for total gross proceeds of $6.8 million, showing it can raise capital, though this alone does not cure the deficiency. The company has until June 1, 2026 to submit a compliance plan and could receive up to October 14, 2026 to regain compliance, but there is no assurance its plan will be accepted or that it will meet the requirement, and a delisting would materially harm its operations and reputation.
Vivos Therapeutics reported full-year 2025 results with higher revenue but sharply wider losses and a weakened balance sheet. Revenue rose to $17.5 million from $15.0 million, a 16% increase, driven mainly by more sleep testing services and treating obstructive sleep apnea patients at two Nevada locations of The Sleep Center of Nevada, which Vivos acquired in June 2025.
Gross profit increased to $10.5 million from $9.0 million and gross margin held at 60%. However, operating expenses climbed to $30.4 million from $20.2 million, reflecting integration and management costs for The Sleep Center of Nevada and related treatment centers, leading to an operating loss of $19.9 million versus a $11.2 million loss in 2024. Net loss widened to $21.2 million.
Cash and cash equivalents declined to $2.0 million as of December 31, 2025, from $6.3 million a year earlier, while current debt reached $8.4 million. Total liabilities rose to $26.7 million and total equity moved from positive $8.0 million to a deficit of $1.6 million. Management highlighted a strategic pivot away from enrolling VIP dentists toward alliances and acquisitions of sleep specialty providers and reiterated its goal of achieving cash flow positive operations by the end of the year.
Vivos Therapeutics reported full-year 2025 results with higher revenue but sharply wider losses and a weakened balance sheet. Revenue rose to $17.5 million from $15.0 million, a 16% increase, driven mainly by more sleep testing services and treating obstructive sleep apnea patients at two Nevada locations of The Sleep Center of Nevada, which Vivos acquired in June 2025.
Gross profit increased to $10.5 million from $9.0 million and gross margin held at 60%. However, operating expenses climbed to $30.4 million from $20.2 million, reflecting integration and management costs for The Sleep Center of Nevada and related treatment centers, leading to an operating loss of $19.9 million versus a $11.2 million loss in 2024. Net loss widened to $21.2 million.
Cash and cash equivalents declined to $2.0 million as of December 31, 2025, from $6.3 million a year earlier, while current debt reached $8.4 million. Total liabilities rose to $26.7 million and total equity moved from positive $8.0 million to a deficit of $1.6 million. Management highlighted a strategic pivot away from enrolling VIP dentists toward alliances and acquisitions of sleep specialty providers and reiterated its goal of achieving cash flow positive operations by the end of the year.
Vivos Therapeutics, Inc. files its annual report describing a major pivot from a legacy dentist-focused distribution model to a medical-provider focused strategy built around sleep centers and managed service organizations. The company acquired The Sleep Center of Nevada (SCN) in June 2025 and is integrating its seven locations into the Vivos platform.
SCN generated $4.8 million of diagnostic revenue and $2.0 million of treatment revenue in 2025, and Vivos plans to scale operations using dedicated Sleep Optimization teams. Management highlights substantial risks, including a history of operating losses, the need for additional capital, integration and regulatory challenges, and dependence on insurance reimbursement and acceptance of The Vivos Method.
Vivos Therapeutics, Inc. files its annual report describing a major pivot from a legacy dentist-focused distribution model to a medical-provider focused strategy built around sleep centers and managed service organizations. The company acquired The Sleep Center of Nevada (SCN) in June 2025 and is integrating its seven locations into the Vivos platform.
SCN generated $4.8 million of diagnostic revenue and $2.0 million of treatment revenue in 2025, and Vivos plans to scale operations using dedicated Sleep Optimization teams. Management highlights substantial risks, including a history of operating losses, the need for additional capital, integration and regulatory challenges, and dependence on insurance reimbursement and acceptance of The Vivos Method.
V-Co Investors 3 LLC, a ten percent owner of Vivos Therapeutics, Inc., filed an initial ownership report on Form 3. It reports direct holdings of 1,353,625 shares of Common Stock, plus a Pre-Funded Warrant for 429,957 underlying shares at $0.0001 per share, and Series A and Series B Common Stock Warrants each covering 1,783,582 underlying shares at an exercise price of $1.09 per share. The Series A warrant expires on March 31, 2028 and the Series B warrant on March 31, 2031, while the Pre-Funded Warrant runs until fully exercised.
Vivos Therapeutics, Inc. entered a Securities Purchase Agreement with V-Co Investors 3 LLC for a private PIPE Offering. The company issued 1,353,625 common shares, a Pre-Funded Warrant for 429,957 shares, and Series A and B Warrants for up to 1,783,582 shares each.
V-Co 3 paid $1.34 per PIPE Share and Pre-Funded Warrant Share with associated warrants, providing $850,000 in cash and converting $1,400,000 previously funded under a bridge note into the PIPE. The Common Stock Purchase Warrants are exercisable at $1.09 per share, while the Pre-Funded Warrant has a $0.0001 exercise price.
The Series A Warrant has a two-year term and the Series B Warrant a five-year term. Warrants include stock-based anti-dilution protection and beneficial ownership limits at 19.99%. Vivos must file a resale registration statement within 45 days and seek effectiveness within 90 days, keeping it effective for up to three years. The company will pay $50,000 of V-Co 3’s counsel fees.
Vivos Therapeutics, Inc. disclosed that V-Co Investors 3 LLC, a ten percent owner associated with Michael C. Skaff, made a series of open-market purchases on March 31, 2026. The entity bought 1,353,625 shares of common stock at $1.34 per share, plus pre-funded and Series A and B common stock warrants at the same price, covering a total of 5,350,746 securities including underlying common shares. A bridge promissory note of $1,400,000 was also converted into common stock based on $1.09 per share plus $0.25 per share under Nasdaq minimum price rules. The Pre-Funded Warrant has a term ending upon complete exercise, while the Series A and Series B warrants have exercise prices of $1.09 and expire on March 31, 2028 and March 31, 2031, respectively. Skaff and SP Manager LLC disclaim beneficial ownership except to the extent of their pecuniary interest.
V-CO Investors LLC, related investment entities, and Michael C. Skaff filed a Schedule 13D disclosing a significant stake in Vivos Therapeutics, Inc.. Through V-CO, V-Co 2, and V-Co 3, they directly hold a total of 2,696,123 common shares, representing 19.9% of the company’s common stock.
On March 31, 2026, V-Co 3 entered a private placement with Vivos, purchasing 1,353,625 shares of common stock at $1.34 per share as part of a $2.39 million subscription. V-Co 3 also received Series A and Series B warrants, each exercisable for up to 1,783,582 shares at $1.09 per share, and a pre-funded warrant for up to 429,957 shares at $0.0001 per share, all subject to a 19.99% ownership cap. The filing states the investment is for general working capital and that the investors’ purpose is primarily investment, while reserving the right to discuss strategy and governance with the company.
Vivos Therapeutics, Inc. notified the SEC that it cannot timely file its Form 10-K for the year ended December 31, 2025 and expects to use the Rule 12b-25 extension.
The company says additional time is needed to complete year-end financial statements and disclosures related to its 2025 acquisition of Prabhu-Lata K. Shete MDs, LTD. d/b/a The Sleep Center of Nevada (SCN). The filing states the company anticipates revenue increased by over 15% for 2025 and that sales, general and administrative expenses rose approximately 50%, contributing to a larger net loss versus 2024. The notification is signed by CFO Bradford Amman and dated March 31, 2026.
Vivos Therapeutics director Gregg C. Johnson filed an initial ownership report showing indirect beneficial ownership of 3,997 shares of Vivos Therapeutics common stock. These shares are held through Spite Family Holdings LP, meaning the position is reported as indirect rather than personally held in his own name.
Vivos Therapeutics, Inc. filed a resale registration covering 3,964,712 shares of common stock issuable upon exercise of two series of investor warrants. A five-year Series A warrant and a 24-month Series B warrant each allow purchase of up to 1,982,356 shares at an exercise price of $2.09 per share.
The company is not selling any shares in this offering and will not receive proceeds from selling stockholder resales, but may receive up to approximately $8.29 million if the warrants are exercised for cash. Vivos will bear registration costs, while the selling stockholder pays its own selling expenses. The registered shares may be sold from time to time on Nasdaq, where Vivos trades under the symbol VVOS.